Tagged With CRISPR Therapeutics

GOLDMAN SACHS: These 8 underappreciated US biotech stocks are cheap and poised to explode higher


A blockbuster gene-editing tool has been linked to cancer -- here's how worried you should be


A blockbuster gene-editing tool has been linked to cancer -- here's how worried you should be



The FDA just put a pause on a cutting-edge gene editing trial that hadn't started yet -- and the company's stock is dropping


Wall Street just freaked out about a potential hiccup to a revolutionary gene editing technology -- but it's not as bad as it seems


A major gene-editing company just inked a $335-million deal with Bayer